Here are 1-3 brief analogies for Seer:

• Illumina for proteins
• 10x Genomics for proteomics

• Proteograph Product Suite: An integrated solution for proteomic studies, encompassing specialized consumables, automation instrumentation, and software.

Seer (SEER) sells its products primarily to organizations for research purposes, rather than to individuals. Based on the provided description, its major customers fall into the following categories:

• Academic institutions
• Life sciences and research laboratories
• Biopharmaceutical and biotechnology companies

Omid Farokhzad, Chair and Chief Executive Officer

Omid Farokhzad is the Chair and Chief Executive Officer for Seer, which he co-founded in 2017. Prior to Seer, he was a Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women's Hospital. Dr. Farokhzad has founded several other companies, including BIND Therapeutics (acquired by Pfizer), Selecta Biosciences (merged with Cartesian Therapeutics), Tarveda Therapeutics, and PrognomiQ, where he serves as Chair of the Board. PrognomiQ was spun off from Seer in 2020. Seer itself received early investments from firms such as Maverick Capital, aMoon Fund, Wing VC, T. Rowe Price, and Fidelity. His extensive history of founding and leading biotechnology companies, many of which have received significant venture capital backing and achieved acquisitions or public listings, demonstrates a pattern of managing companies backed by private capital.

David R. Horn, President & Chief Financial Officer

David R. Horn is the President & Chief Financial Officer for Seer, joining the company in 2020. Before joining Seer, Mr. Horn spent over 20 years at Morgan Stanley as a Managing Director in the firm's Global Healthcare Group within the Investment Banking Department. In this role, he was responsible for Morgan Stanley's global Life Science Tools and Diagnostics practice and oversaw the Western Region Healthcare practice. Mr. Horn also served as Vice President of Business Development at RITA Medical Systems and Chemdex Corporation. While he has not founded companies, his extensive career in investment banking within the healthcare and life sciences sectors, including advising on strategic and financing initiatives, indicates deep experience with companies often backed by private equity.

Marissa Dixon, Chief People Officer

Marissa Dixon is the Chief People Officer at Seer. Prior to Seer, she was the Vice President of Human Resources at CareDx, where she contributed to significant business growth. She brings over 20 years of human resources leadership experience, having held various HR roles with increasing responsibility in the biotech industry at companies such as Metabiota and DuPont Industrial Biosciences.

Serafim Batzoglou, Chief Data Officer

Serafim Batzoglou serves as the Chief Data Officer at Seer. He co-founded DNAnexus Inc. in 2009. He was also a Professor of Computer Science and Biomedical Data Sciences at Stanford University for 15 years, and a member of the Stanford AI Lab (SAIL).

Kenny Ross, Chief Operations and Product Officer

Kenny Ross is the Chief Operations and Product Officer at Seer.

Key Risks to Seer (SEER)

1. High Cash Burn Rate and Path to Profitability: Seer, Inc. is characterized as a "cash-rich, pre-profit" company facing a significant cash burn rate and modest revenue growth that struggles to keep pace with its high fixed costs. The company reported a net loss of $18.2 million on revenue of $4.1 million in Q3 2025, with a free cash flow loss of approximately $35.1 million for the first nine months of 2025. While Seer possesses a substantial cash cushion, its financial runway is not infinite, and the biggest question for investors is whether its innovative proteomics platform can outpace this cash burn and achieve a viable financial model. The company's projected revenue growth for 2026 is only about 3%, and expected cash burn exceeds $40 million, leading to significant investor dissatisfaction regarding financial performance and strategy.

2. Market Adoption and Intense Competition: Seer's business heavily relies on the widespread adoption of its proteomics technologies by researchers and institutions. Despite a growing installed base and scientific validation, the company faces challenges in converting this into consistent and recurring consumables revenue. The proteomics market is highly competitive, with established players and new entrants potentially pressuring Seer's market share. The company's ability to accurately forecast demand and translate scientific interest into a robust commercial model is crucial but has been a challenge, as evidenced by substantial revenue misses.

3. Macroeconomic Headwinds and Research Funding Constraints: External economic factors and uncertainties in research funding pose significant near-term risks to Seer's business. The prevailing macroeconomic environment has led to elongated sales cycles and capital spending constraints among its key customers, including biopharmaceutical companies and academic institutions. Furthermore, shifting government policies and uncertainties regarding NIH grant funding directly impact the capital available to academic customers, which is a major source of demand for Seer's products. These external headwinds can dampen customer spending decisions and hinder the company's revenue growth.

The addressable market for Seer's main products and services, primarily its Proteograph Product Suite, is the global proteomics market. The proteomics market involves the large-scale study of proteins, which are crucial for understanding biological functions and disease mechanisms.

The global proteomics market was valued at approximately USD 41.2 billion in 2025. This market is projected to experience significant growth, with estimates placing its value at around USD 99.8 billion by 2032 and USD 126.3 billion by 2035. The compound annual growth rate (CAGR) for this period is expected to be between 12% and 13.6%.

North America is a dominant region in the proteomics market, holding a substantial share. In 2025, North America's proteomics market was valued at USD 19.9 billion and held approximately 43.75% of the global market share. It is projected to reach USD 61.9 billion by 2035.

Seer, Inc. (NASDAQ: SEER) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies:

1. Growth in Installed Base and Consumable Sales: A primary driver of revenue growth is the expansion of the company's Proteograph instrument installed base and the subsequent increase in consumable kit sales. Seer operates on a "razor-and-blade" model, where instrument placements generate recurring revenue from the sale of consumable kits. The company reported a significant increase in its installed base, with 82 instruments deployed by the end of 2025, a 67% increase compared to 2024, and a roughly 69% year-over-year growth in consumable kit volume. This indicates a growing adoption of their core technology, which is expected to translate into sustained consumable pull-through.
2. New Product Innovation and Expanded Applications: Seer is focusing on product innovation to expand its platform's capabilities and addressable market. Recent and planned launches include the high-throughput Proteograph ONE assay and the accompanying SP200 automation instrument, which doubles throughput and significantly reduces per-sample analysis costs. Future innovations like the fourth-generation Proteograph Analysis Suite (PAS) with AI capabilities and a proteoform profiling assay kit in 2027 are also expected to enhance the platform's utility and attract a broader user base.
3. Expansion of the Seer Technology Access Center (STAC) Program and Customer Conversion: The Seer Technology Access Center (STAC) program, which provides end-to-end services from sample to data, is a crucial avenue for customer acquisition and service revenue. The company has expanded its STAC program, including into Europe, generating service revenue and serving as a funnel for converting customers to outright instrument purchases. Approximately 50% of instruments installed during 2025 represented conversions from previous STAC customers, demonstrating the effectiveness of this strategy.
4. Strategic Instrument Placement Program (SIPP) and Population-Scale Studies: Seer is actively pursuing the Strategic Instrument Placement Program (SIPP) to accelerate the deployment of its Proteograph instruments. This program, which accounted for approximately 60% of instruments installed in 2025, aims to expand the company's installed base. Additionally, securing partnerships for large population-scale studies (e.g., 20,000 and 10,000 samples) is a significant growth driver, as these studies not only validate the technology but also lead to substantial instrument placements and increased consumable usage.

Share Repurchases

• Seer, Inc. authorized a $25 million share repurchase program in May 2024.
• Through December 31, 2025, approximately $22 million of the authorized program was utilized, leading to the repurchase of about 11.7 million Class A common shares and reducing total outstanding shares by approximately 13%.
• In 2025 alone, the company repurchased approximately 5.3 million shares, returning around $10.2 million in cash to shareholders. An additional $25 million share repurchase authorization was approved in February 2026.

Share Issuance

• In February 2021, Seer, Inc. completed an underwritten public offering, selling 1,650,000 shares of Class A common stock at $67.00 per share, raising approximately $110.55 million for the company.

Inbound Investments

• No significant large equity investments made in Seer by third-parties (such as strategic partners taking equity stakes or private equity firms) for capital raising purposes have been publicly disclosed within the 2021-2025 timeframe.

Outbound Investments

• No instances of Seer, Inc. making strategic investments in other companies (e.g., acquisitions or equity investments in other firms) have been identified within the 2021-2025 period.

Capital Expenditures

• Capital expenditures were reported as minimal, at approximately $0.97 million for the trailing twelve months as of Q3 2025.
• In the fourth quarter of 2025, capital expenditures totaled $292K.
• For the full year 2025, capital expenditures were stated as $1.8 million.